Podiatrists in White River Junction, VT Accepting Medicare
3 Podiatrists found. Showing 1 - 3
 Dr. Joseph Patrick Duggan, DPM Podiatrist - Foot Surgery Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 |
Dr. John Edward Connolly, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: White River Junction Vamc, Desk 90 (112), White River Junction, VT 05009 Phone: 802-291-6290 Fax: 802-296-6329 |
 Caroline Elizabeth Whittington, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-291-6290 |
News Archive
Researchers discover important link between Parkinson's and prion diseases
Parkinson's disease and prion diseases are very different from each other as regards both origins and course. Nonetheless, a research group of SISSA's, headed by Professor Giuseppe Legname, has discovered an unexpected and important link between the two pathologies.
Researchers find new cost-effective way to predict interaction of chemical compounds
New research has revealed that simple, commercially available computer programs could be used to design next generation drug-delivery systems by predicting more easily how different chemical compounds interact.
Symposium examines Bruesewitz vs. Wyeth Supreme Court case
A March 29 symposium at the New York Academy of Sciences, "Vaccines Under the Gun: Politics, Science, Media and the Law," will feature a presentation by Daniel J. Thomasch, JD, national lead trial counsel for Wyeth, who was involved in the case decided by the Supreme Court yesterday in which the justices rejected a lawsuit claiming injury from a Wyeth vaccine.
The OpenHIE community to hold second annual community meeting in Ethiopia
The OpenHIE community will hold its second annual community meeting November 4-8, 2019 in Addis Ababa, Ethiopia. Between 200 and 300 individuals are expected to attend with the ultimate goal of development and efficient and effective operation of national and regional health information exchanges.
Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
› Verified 7 days ago
Optometrists
Physical Therapists
Audiologists
Chiropractors
Occupational Therapists
Speech-Language Pathologists
Podiatrists